A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations
NCT07863635
This study is recruiting at 5 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1283 and mRNA-1273 (variant formulations) within the current epidemiological environment
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- SARS-CoV-2
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- ModernaTX, Inc.
- Last updated on ClinicalTrials.gov
- October 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Kansas · 1
- Delricht Research @ Overland · Overland Park, KS
Kentucky · 1
- Delricht Research @ Louisville · Louisville, KY
North Carolina · 1
- Delricht Research @ Charlotte · Charlotte, NC
Tennessee · 1
- Delricht Research @ Magnolia Family Medicine · Hendersonville, TN
Texas · 1
- Delricht Research @ Zomnir Family Medicine · Prosper, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.